Neurocrine Biosciences, Inc.

Your program is about to begin. Good day, everyone, and welcome to today's Neurocrine Biosciences reports third quarter results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. Please note today's call may be recorded, and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla. Please go ahead.

Thank you, Chloe. Good afternoon, and thanks for joining our third quarter 2021 earnings call. On today's call is Kevin Gorman, our Chief Executive Officer, Matt Abernethy, our Chief Financial Officer, Eiry Roberts, our Chief Medical Officer, Eric Benevich, our Chief Commercial Officer, and Kyle Gano, our Chief Business Development and Strategy Officer. During our call today, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After our prepared remarks, we'll go into the question and answer session, so please limit yourself to one question so we can get to as many questions as possible. With that, I hand the call over to Kevin Gorman.

Thanks, Todd. Welcome, everyone. Good afternoon. I'm just going to start out with two brief comments. First, I'm very pleased to see Ingress' continued growth. This is the second quarter in a row where we see this growth, and I anticipate we're going to have continued growth for the remainder of the year. Now, we're not yet back to pre-COVID growth trajectory, but NRX has continued to increase. COVID's impacts are still being experienced in the field in a number of territories. It is not behind us, but we've adapted well. In addition, telemedicine is still being heavily utilized by healthcare professionals. But again, we are adapting well and growing our business. And Eric will talk about how we are investing behind Ingresa. Now, second, we started the year with an extremely aggressive goal to start a number of phase two and phase three clinical trials. And we are going to meet that goal, growing one of the most robust neuroscience pipelines in the industry. And I will highlight several of these programs. So with that, I'm going to turn it over to Matt.